Igor Bondarenko

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial”.

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet(2024)10.1016/s0140-6736(24)01756-2

N/A

3.7DataRank · unranked

262 citations

Marina Chiara Garassino, Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi +91 more

Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology(2010)10.1200/jco.2010.28.15_suppl.7531

N/A

3.0DataRank · unranked

53 citations

I. N. Bondarenko, A. Luft, P. Serwatowski, Fabrice Barlesi, R. T. Chacko +14 more